as 12-18-2024 9:49am EST
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company operates in a single segment: research and development, manufacturing, and commercialization of innovative pharmaceutical products. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.
Founded: | 2015 | Country: | Canada |
Employees: | N/A | City: | MARKHAM |
Market Cap: | 6.1M | IPO Year: | N/A |
Target Price: | $21.00 | AVG Volume (30 days): | 31.2K |
Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.93 | EPS Growth: | N/A |
52 Week Low/High: | $1.69 - $5.99 | Next Earning Date: | 02-07-2025 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
EDSA Breaking Stock News: Dive into EDSA Ticker-Specific Updates for Smart Investing
Simply Wall St.
a day ago
GlobeNewswire
5 days ago
GlobeNewswire
2 months ago
GlobeNewswire
2 months ago
Zacks Small Cap Research
4 months ago
ACCESSWIRE
6 months ago
Zacks Small Cap Research
7 months ago
ACCESSWIRE
7 months ago
The information presented on this page, "EDSA Edesa Biotech Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.